Comparing the current results to its competitors, Xtl Biopharmaceuticals Ltd reported Revenue decrease in the 4 quarter 2023 year on year by 0 %, slower than the combined decrease of the XTLB's competitors by -3.54 %, recorded in the same quarter.
Xtl Biopharmaceuticals Ltd , slower than the average decrease reported by the company's competitors of -7.83 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -7.83 %
Xtl Biopharmaceuticals Ltd 's Comment on Competition and Industry Peers
The company maintains its competitive position through trade secrets, technical expertise, innovation, and third-party agreements. U.S. patent applications remain confidential for at least 18 months; however, issued patents can be challenged, circumvented, or invalidated at any time. Invalidation in one jurisdiction may impact patent rights in others. The company may incur substantial costs when challenging competitors' patent applications that claim overlapping technology, regardless of the outcome. While the company has the right, but not the obligation, to defend licensed patent rights, it must bear all related expenses if it chooses to do so. If a third party obtains a patent with claims conflicting with the company's technology, the company may need to obtain a license or develop alternative solutions.
Publicly Traded Peers of Xtl Biopharmaceuticals Ltd
Astrazeneca Plc Share Performance
+1.32%
One Year
Astrazeneca Plc
Profile
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Eqrx Inc is a pharmaceutical company that focuses on creating affordable and accessible medication. They employ an innovative business model that combines research and development with scientific expertise to develop generic alternatives to the high-priced drugs in the market. By bypassing the traditional pharmaceutical pricing system, Eqrx aims to make essential medications more affordable for patients and healthcare providers.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Sources:
Xtl Biopharmaceuticals Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Xtl Biopharmaceuticals Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
